 9. Subject is and has been receiving a medication that is known to strongly inhibit andor induce cytochrome P450 2C9 such that it might unpredictably affect the pharmacokinetics of diclofenac e.g., fluconazole, amiodarone, oxandrolone, sulfipyrazone as inhibitors and rifampin as an inducer. 